Pyxis Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Pyxis Oncology's estimated annual revenue is currently $11.7M per year.
- Pyxis Oncology's estimated revenue per employee is $147,570
- Pyxis Oncology's total funding is $174M.
- Pyxis Oncology's current valuation is $337.5M. (January 2022)
Employee Data
- Pyxis Oncology has 79 Employees.
- Pyxis Oncology grew their employee count by -7% last year.
Pyxis Oncology's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Chief Staff, Medical | Reveal Email/Phone |
3 | VP, Facilities & Business Operations | Reveal Email/Phone |
4 | Head Analytical Development and QC | Reveal Email/Phone |
5 | SVP, Head Global Regulatory Affairs | Reveal Email/Phone |
6 | VP, R&D Quality | Reveal Email/Phone |
7 | VP, Investor Relations | Reveal Email/Phone |
8 | VP, Head Discovery | Reveal Email/Phone |
9 | SVP, Portfolio and Project Management | Reveal Email/Phone |
10 | SVP Head Non-Clinical Research | Reveal Email/Phone |
Pyxis Oncology Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Pyxis Oncology?
Pyxis Oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.
keywords:N/A$174M
Total Funding
79
Number of Employees
$11.7M
Revenue (est)
-7%
Employee Growth %
$337.5M
Valuation
N/A
Accelerator
Pyxis Oncology News
Get Pyxis Oncology alerts: Large investors have recently bought and sold shares of the company. Citigroup Inc. bought a new position in shares...
Pyxis Oncology Announces Leadership Changes. Published: Apr 13, 2022. Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer; Jan Pinkas, Ph.D.,...
Pyxis Oncology, Inc. is a multi-asset, multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By...
It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline. This also built on the ADC licensed from LegoChem Biosciences late last year, now known as PYX-202, for ...
Arix Bioscience PLC (ARIX) Arix leads USD152 million Series B financing for Pyxis Oncology 30-March-2021 / 13:01 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =--------------------------------- ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $21.3M | 79 | 11% | N/A |
#2 | $11.9M | 79 | -1% | N/A |
#3 | $21.3M | 79 | 7% | N/A |
#4 | $18M | 79 | 32% | N/A |
#5 | $17.4M | 79 | 7% | N/A |